NAD+ Injection Cost: Clinic, Telehealth, At Home

Key takeaways

• In October 2026, at-home NAD+ injections prescribed through telehealth cost about $105 to $350 a month, NAD+ nasal spray $116 to $200 a month, and a clinic IV drip $250 to $1,500 per session. Insurance covers none of it.
• Over a year, that is roughly $1,260 to $4,200 for injections, $1,392 to $2,400 for nasal spray, and $3,000 to $18,000 for one IV session a month.
• The headline price leaves out membership fees, shipping, supplies and any vial that outlasts its beyond-use date; the calculator below turns a quote into a real monthly figure.
• The money buys a legal compounded product, made under FDA's interim Category 1 policy, but not evidence: no controlled trial has tested NAD+ injections or drips against a health outcome, and the route with the most data, oral precursors, is the cheapest.
• Ask the pharmacy what grade of NAD+ it uses and whether it tests for endotoxin: FDA warned about food-grade NAD+ in injectables in 2024, and a Class I recall followed in 2025.

How much are NAD injections? In October 2026, telehealth programs list at-home NAD+ injections at about $105 to $350 a month, nasal spray at $116 to $200 a month, and clinics charge $250 to $1,500 for each IV session (HealingMaps). Insurance pays for none of it. Those figures come from our peptide therapy cost guide, collected October 9, 2026, and you can run any quote through our peptide cost calculator, the parent page for this one. NAD+ is a coenzyme rather than a peptide, but it is sold alongside them; for a peptide that has no legal price at all, see what BPC-157 costs at a clinic versus online.

NAD+ cost by route, October 2026

The pattern in that table is the one our NAD+ profile points out: the price rises as the evidence falls. The route with controlled trials behind it is a capsule; the routes that cost the most have the least data.

Clinic, telehealth or at home: what sets the price

Clinic IV. You pay per visit, and the price tracks the dose and the time in the chair. Drips typically carry 250 to 1,000 mg over one to four hours, and they run long for a reason: in a retrospective review at a commercial clinic, clients given 500 mg a day for four days reported moderate to severe stomach symptoms, a faster heart rate and chest pressure during the drip, and their infusions averaged 97 minutes, against 37 minutes for nicotinamide riboside, because the drips were slowed (Reyna 2026). Many clinics sell multi-day series or memberships, which is where the annual cost climbs.

Telehealth. A program writes the prescription, a compounding pharmacy ships the vial or spray, and the monthly fee usually bundles both. Check whether visits, supplies and shipping are inside the price, and whether the price assumes the lowest dose on the longest commitment.

At home. Once the vial is in your refrigerator, your cost depends on four numbers: the dose, how often you inject, how much NAD+ is in the vial, and the vial's price. The calculator below opens on example inputs, not a quote and not a recommendation: a 500 mg vial priced at $100, injected at 100 mg twice a week. The dose field is in micrograms, so 100 mg is entered as 100,000.

With those placeholders, medication costs about $173 a month and $2,080 a year, and one vial lasts about 18 days, which sits inside the $105 to $350 range above. The 100 mg twice-weekly schedule is within the 50 to 100 mg one to three times a week that clinic listings use; no study has tested any of those schedules, so the dose on your pharmacy label is the one that counts. For the syringe arithmetic, the NAD+ profile works through a labeled vial, and the units converter does the rest.

Hidden costs

• Membership or platform fees: $0 to $100 a month at some programs, on top of the medication.
• Supplies and shipping: $5 to $25 a month for syringes, swabs and a sharps container, and $0 to $30 per cold-chain shipment, when they are not included.
• First visit and labs: $0 to $200 for an initial consultation where it is not bundled; labs are not always ordered for NAD+, but a baseline panel adds $100 to $400 when it is.
• The vial you throw away: a multi-dose vial is good only until the beyond-use date on its label. If your schedule stretches a vial past that date, the leftover is wasted and your real monthly cost is higher than the calculator shows; our storage guide explains the dates.
• Series and packages: IV clinics often price by the series. Four drips at $250 to $1,500 each is $1,000 to $6,000 before anything is measured.

What the money buys, and what the evidence shows

Paying for NAD+ through a licensed pharmacy buys a legal product: NAD+ sits in Category 1 of FDA's interim 503A list, so pharmacies may compound it while FDA evaluates it, although FDA proposed in 2019 not to add it to the permitted list and has not finished that rulemaking (legal tracker). It does not buy a demonstrated benefit. The NAD+ profile grades the evidence in full; for a cost decision, four findings matter.

• Infused NAD+ is broken down fast. In the only pharmacokinetic study, a six-hour infusion produced no rise in plasma NAD+ or its metabolites for the first two hours; the molecule was removed from plasma rapidly and completely, in a pattern consistent with enzymes that cut NAD+ apart outside cells (Grant 2019).
• The drip evidence is thin. A 2026 review of intravenous NAD+ found only small uncontrolled studies, observational work and case reports, listed nausea, cramping, flushing and chest discomfort as the reported adverse effects, and concluded the evidence is insufficient to support routine clinical or wellness use (Alangari 2026).
• Injections and sprays have no trials. We found no published human study of subcutaneous, intramuscular or nasal NAD+, the products most telehealth programs sell.
• The cheap route has the data, and it is modest. A 2026 meta-analysis of 15 randomized trials of oral NMN at 250 to 2,000 mg a day found it well tolerated but with no effect on body weight, BMI, fasting glucose, HbA1c or lipids (Yang 2026). The largest outcome trial of a precursor, NOPARK, gave 410 people with early Parkinson's disease nicotinamide riboside 500 mg twice daily or placebo for a year; total symptom scores ended 2.72 points worse on the supplement than on placebo (Brakedal 2026).

Quality: the question to ask before you pay

The risk that has actually hurt people is the product, not the molecule. In 2024 FDA said some compounders were making injectable NAD+ from food-grade material, with adverse-event reports of severe chills, shaking and vomiting consistent with endotoxin contamination (FDA 2024), and a Class I recall of an NAD+ injection followed in 2025 (Gavura 2026). A cheaper price is worth nothing if the vial is contaminated. Ask which pharmacy fills the prescription, whether it is a 503A pharmacy or a 503B outsourcing facility, whether it uses pharmaceutical-grade NAD+, and whether it tests for sterility and endotoxin. Research-grade NAD+ powder sold online with mixing instructions is exactly the material FDA warned about, whatever it costs.

Insurance, HSA and FSA

Insurance covers no NAD+ product. HSA and FSA funds can pay for prescribed medicines, but IRS Publication 502 says medical care must be primarily to alleviate or prevent a physical or mental disability or illness, and does not include expenses that are merely beneficial to general health (IRS Publication 502). Whether a prescribed NAD+ vial qualifies depends on why it was prescribed and on your plan; a spa drip without a prescription and NR or NMN supplements bought for general health generally do not. Ask your plan administrator and keep the prescription and an itemized receipt.

Bottom line

NAD+ injections cost about $105 to $350 a month at home through telehealth, nasal spray $116 to $200, and clinic drips $250 to $1,500 a session, which can mean $3,000 to $18,000 a year for monthly IVs. The money buys a legal compounded product from a pharmacy you should be able to name, but no controlled trial of injections or drips has shown a health benefit, and the cheapest route, an oral precursor, is the one with the most data. If you go ahead, price the year, check the beyond-use date against your schedule, and ask about the NAD+ grade and endotoxin testing before you pay.

Frequently asked questions

+−How much are NAD injections?

In October 2026, telehealth programs list at-home NAD+ injections at about $105 to $350 a month, usually with the prescription and the vial included. Nasal spray costs about $116 to $200 a month, and a clinic IV drip costs $250 to $1,500 per session depending on the dose and the city. Insurance does not cover any of it.

+−How much does an NAD IV drip cost?

About $250 to $1,500 per session at clinics and IV lounges in October 2026. The price rises with the dose and the time in the chair, and many clinics sell multi-day series or monthly memberships. One session a month works out to $3,000 to $18,000 a year, and a four-day series to $1,000 to $6,000.

+−Why is an NAD+ IV so much more expensive than injections?

You pay for the clinic's time, staff, chair and IV supplies, and a drip delivers a much larger dose, often 250 to 1,000 mg, over one to four hours. An at-home injection uses a smaller dose from a multi-dose vial you inject yourself. Neither route has a controlled trial showing a health benefit, so the higher price buys a bigger dose and an experience, not better evidence.

+−Does insurance cover NAD+ injections, and can I use my HSA?

Insurance covers none of it. HSA and FSA funds can pay for prescribed medicines under IRS Publication 502, but medical care must be primarily to alleviate or prevent an illness and does not include expenses merely beneficial to general health. A prescribed NAD+ vial may or may not qualify depending on why it was prescribed; a spa drip without a prescription and NR or NMN supplements generally do not. Ask your plan administrator first.

+−What does the NAD injection do?

Measurably, it raises NAD+ and its breakdown products in the blood for a few hours. In the one pharmacokinetic study, infused NAD+ was removed from plasma almost completely for the first two hours, and the breakdown products pointed to enzymes outside cells rather than uptake into them. What that does for energy, aging or recovery has never been tested in a controlled trial, and no study has tested subcutaneous or intramuscular injections at all.

+−What is the downside of taking NAD?

Fast IV infusions cause nausea, cramping, flushing, a faster heart rate and chest pressure, which ease when the drip slows or stops. The larger risk is product quality: in 2024 FDA warned about injectable NAD+ made from food-grade powder, with reports consistent with endotoxin contamination, and a Class I recall followed in 2025. Long-term safety has not been studied, and the cost adds up to thousands of dollars a year.

+−Is NAD like Ozempic?

No. Ozempic is semaglutide, a GLP-1 drug with large outcome trials for weight and blood sugar. NAD+ is a coenzyme with no weight-loss trial in humans, and a 2026 meta-analysis of 15 trials of oral NMN found no effect on body weight, BMI, glucose or HbA1c. Some clinics bundle NAD+ with a GLP-1 drug; there is no trial of that combination.

Sources

1. SourceHealingMaps. How much does NAD+ therapy cost in 2026? IV drips vs injections vs nasal spray (affiliate site). Read for our cost guide, October 2026. (2026)
2. StudyGrant R et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci 2019;11:257. (2019)
3. StudyReyna K et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging 2026;7:1652582. (2026)
4. ReviewAlangari A et al. Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine. Front Aging 2026;7:1887175. (2026)
5. ReviewYang W et al. Safety and metabolism-related outcomes of oral nicotinamide mononucleotide supplementation in adults: a systematic review and meta-analysis. Nutrients 2026;18:2251. (2026)
6. StudyBrakedal B et al. Nicotinamide riboside for patients with early-stage Parkinson disease: the NOPARK randomized clinical trial. JAMA 2026 (published online October 8, 2026). (2026)
7. RegulatoryFDA. FDA reminds compounders to use ingredients suitable for sterile compounding (food-grade NAD+ used in injectable products; adverse event reports consistent with endotoxins). 2024. (2024)
8. SourceGavura S. Science vs. hype: the unproven promise of NAD+ IV therapy. Science-Based Medicine, July 16, 2026 (reports the 2025 Class I recall of an NAD+ injection). (2026)
9. RegulatoryIRS. Publication 502 (2025), Medical and Dental Expenses: what medical expenses are; medicines. (2025)